Diabetes & Metabolic Syndrome · Nov 2026
Strengths and Limitations of Synthetic Versus Reference Semaglutide in Indian Adults with Type 2 Diabetes or Obesity: A Systematic Review and Critical Appraisal of Published Phase III Evidence
By Singh AK, Singh A, Singh R et al.
Background and aims To date, eight randomized Indian Phase III trials have compared chemically synthesized injectable semaglutide with reference products. We systematically reviewed their efficacy, dose exposure, safety, immunogenicity, reporting, and risk of bias. Methods We searched PubMed through 10 September 2026 and supplemented this with Google Scholar, registry, citation, journal-site, and DOI searches. The updated PubMed search returned 132 records, with one additional eligible non-PubMed report. Two reviewers independently verified eligibility, extracted data, and assessed primary outcomes using the Cochrane Risk of Bias 2 tool. Because formulations and clinical questions were not comparable, we synthesized findings without meta-analysis. Results Eight trials from five formulation/manufacturer programs were eligible: five in type 2 diabetes (T2D; 1,483 randomized participants) and three in obesity (798), totaling 2,281 participants. Three T2D trials met a reported 0.4-percentage-point glycated hemoglobin (HbA1c) non-inferiority margin. Murthy et al. reported −0.30 percentage points (95% CI, −0.54 to −0.05), meeting the statistical NI criterion for any positive margin; they did not report a prespecified numerical margin. WIN-IND did not demonstrate NI (upper 95% CI +0.47; margin +0.40). All three obesity trials met their reported 4.5–5.0-percentage-point margins. Three primary results had low risk of bias, and five had some concerns. T2D trials used response-guided dosing, whereas obesity trials provided only about eight weeks at 2.4 mg. Conclusions Short-term efficacy was generally supported, but these trials did not establish fixed-dose or long-term equivalence, device equivalence, interchangeability, switching safety, or cardiovascular-kidney outcome equivalence.